. A large-scale quality assurance audit in a community cancer partner network is feasible. Recent evaluation of localized breast cancer shows high compliance with guidelines and identifies areas for focused education. Partnership between academic and community oncologists produces a quality review process that is broadly applicable and adaptable to changing medical knowledge. (JNCCN 2007;5:875-882) 
Development and Implementation of a

Background
As medical treatment guidelines and quality measures for cancer care continue to develop, academic and community hospitals are challenged to assess, educate, implement, evaluate, and continuously monitor compliance. There is increasing pressure on the medical oncology community to practice evidence-based medicine, which includes the implementation of quality control measures, use of multidisciplinary decision-making, and standardization of care against quality benchmarks.
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Hospitals expect oncologists and accrediting bodies to help guide quality development in their settings. In turn, oncologists rely on national consensus standards developed by academic centers, accrediting bodies, and payors to set the standard of care for the hospitals and private practices in which they work. The large number of quality measures developed by the American College of Surgeons, the National Quality Forum, and the joint collaboration by the National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) has significantly influenced medical oncologists in both practice management and quality improvement. [4] [5] [6] Of these, oncologists in practice most commonly use the NCCN treatment guidelines (the most recent guidelines are available on the Internet at www.nccn.org). Developed through a collaboration of 21 National Cancer Institute (NCI)-designated cancer centers and updated annually, these guidelines contain extensive algorithms for treatment decision-making and encompass 95% of cancer diagnoses.
As a founding member of the NCCN and the academic base for the nation's first known cancer affiliate program, Fox Chase Cancer Center (FCCC) is uniquely positioned to promote quality assurance initiatives at the community level. Established in 1986 as Fox Chase Network, Fox Chase Cancer Center Partners (FCCCP) is a select group of 25 communitybased hospitals throughout southeastern Pennsylvania and New Jersey whose cancer programs are affiliated with FCCC in Philadelphia, Pennsylvania (Figure 1 ). The program has several primary missions, including documenting quality care at affiliate sites and promoting community-based research.
Purpose
Through FCCCP, FCCC collaborates with community hospitals to translate NCCN guidelines to communitybased medical oncologists and monitor guideline compliance in the private practice medical oncology office setting. Building on the authors' pilot experience, 7 the FCCCP program developed a full quality implementation and monitoring plan to measure compliance with NCCN guidelines. This article reviews the evolving experience over the past 7 years in implementing this process. In addition, recent data generated during the last full audit for the evaluation and treatment of stage II/III breast cancer is presented in more detail. (Table 1) .
Methods
Phase I: Education and Dissemination of NCCN Guidelines
Phase I of this process began with a routine discussion and dissemination of the NCCN guidelines at all FCCCP sites. This was accomplished by working with the cancer registrars, community hospital operations directors, and medical directors and chairpersons of each community partner cancer committee. Every year, the FCCCP Senior Project Manager or the Director of Clinical Operations delivered 5 CDs containing electronic versions of the NCCN guidelines (as documented on the NCCN Web site; www.nccn.org) to each community hospital site and promoted discussion about guideline use at the cancer committee meeting. NCCN guidelines were subsequently used during tumor board conferences, grand rounds, and disease-specific case conferences, and as a key component of every FCCC regional continuing medical education session held for FCCCP institutions. Continuing medical education programs were specifically planned each year to correspond to a quality improvement initiative in the FCCCP audit process.
Phase II: Selection of Annual Disease Site and Data Management Considerations
Each year, the FCCCP Clinical Operations team worked with the FCCC medical oncology staff and community oncologists to select a disease site for a yearly audit. The specific disease site was chosen based on disease incidence and recent practice-altering changes to NCCN guidelines. An example is the selection of stage III colon cancer based on the recent incorporation of oxaliplatin into standard adjuvant therapy. 8 An expert panel of FCCC oncologists then selected critical indicators for review and worked with the Director of Clinical Operations to develop a metrics tool that encompassed the patient's full course of therapy from staging through treatment and follow-up. This draft tool was then shared with FCCCP community medical oncologists in 3 formats for edits and comments. It was initially e-mailed directly for comment by replying to the Associate Medical Director. Secondly, the Associate Medical Director of FCCCP and the participating community medical oncologists have a teleconference to review the disease site, rationale for study, and indicators with evidencebased documentation. Thirdly, the medical directors at each Partner institution individually reviewed the draft tool. This process captured comments from all participants in formats acceptable to busy clinicians.
When the audit tool was defined and accepted, a data dictionary was constructed to discuss each indicator in detail to increase auditor comfort level with identifying accurate medical record information. An audit of FCCC charts to test the tool was conducted before dissemination at FCCCP sites. A relational database (PRESAGE) was used most recently by specific office practices and physicians to capture data. audit tool with Senior Project Managers. This team of 5 acts as the auditors for the on-site review. An internal education session reviewed critical features of the audit tool, including pathology, surgical excision terminology, review of systemic treatment regimens and dosing, tumor registry staging criteria, and discussion of current disease-specific clinical trials. To maintain audit reliability, the Director of Clinical Operations went on-site with the Senior Project Managers to jointly conduct the first audit. The Associate Medical Director, a treating oncologist, handled any discrepancies or questions that arose during or after the audit.
An initial letter of invitation was sent to all practicing medical oncologists within FCCCP asking them to participate in that year's medical oncology audit. When the medical oncologists accepted the invitation, their Office Practice Manager and the associated Although different each year, the audit tool routinely contains key elements, summarized in Table 2 .
Phase IV: Audit Report, Implementation of Best Practice Methodologies
On the day of the audit, the team verbally reported the outcome to the medical director or medical oncologist who had approved the audit and the office practice manager or nurse coordinating the audit. Some medical oncologists shared the report with the Director of Operations at their affiliated hospital. They were then able to use the report as a cancer committee quality improvement measure for accreditation purposes, because it encompassed an evaluation of treatment decision-making and best practice methodologies to improve overall patient care. A written audit report was made available within 2 weeks. This provided an opportunity for the FCCCP Medical Director and Associate Medical Director to review the raw audit data for calculating quantitative analysis of guideline implementation and gathering the best practice methodologies for each standard for the final report. An example of an audit report is provided in Figure 2 .
The audit team wrote individualized practice reports. In addition, a cumulative benchmark summary was provided that included all participants with blinded identifiers. The audit results assessed compliance to each indicator and provided a percentage of compliance.
Often FCCC, NCCN institutions, and community Partner sites share tools to improve documentation in certain areas of the audit. Policies and procedures are shared for development of an informed consent form and disease-specific indicators, such as genetic risk assessment and pain management documentation, and for assessing patients for clinical trials. 
Synopsis:
• 20 cases of breast cancer stages T2 through and including T3, N2, M0 stage II, III were reviewed utilizing a 26 point indicator quality improvement tool based on National Comprehensive Cancer Network guidelines (See attached data tool with chart detail).
• Please note an Electronic Medical Record (EMR) system was used to capture all of the data elements. We want to thank Dr. XX for saving us 3 hours of additional workload. The EMR was a great resource and incredibly easy to use.
• Compliance was noted in the following areas: ❍ Good documentation with staging, documentation of unilateral vs. bilateral disease, patient age at diagnosis, hormonal status, multidisciplinary consultation. As sentinel lymph node technique came into accepted practice of care noted less full axillary node dissections completed. Generally 8 nodes or more were examined if axillary dissection was completed. Good follow-up and family history documentation with referral to the high-risk genetic counseling program. We noted Adriamycin, Cytoxan, and Taxol • Tools that could be utilized include: ❍ Patient flow sheet additions to include screening colonoscopy question for any patient older than 50 years and GYN history at least annually. ❍ Since Dr. XX has led the way with an EMR, perhaps linking to the hospital system in some way could help to make sure hospital based diagnostics can be added easily to the system to complete the medical record. ❍ See below table of top accruing studies within FCCCP to give some additional studies you may wish to consider for your breast cancer patient population both treatment and high-risk.
Questions and comments may be directed to Peg O'Grady at Fox Chase Cancer Center Partners. Phone: 215-728-3832; E-mail: Peg.OGrady@fccc.edu The lowest compliance was noted for dissection of 8 or more lymph nodes in patients who had positive sentinel lymph node biopsy (72.6%) and for documentation of radiation oncologist consultation (77.2%). In addition, health maintenance recommendations, such as screening colonoscopy and consultation of a gynecologist, were only documented in 24.6% and 35% of the charts, respectively. However, these variances may partially be affected by a short interval from diagnosis in some patients undergoing adjuvant treatment at audit.
After completion of the audit, all participants received the benchmarked information specific to breast cancer outcomes. They also received a survey asking how audit results impacted their practice. Among the 15 of 16 practices that responded, 53% reported that they used the tools provided to improve chart documentation; 13% initiated new clinical trials in that disease site; 13% conducted staff education; and 6% built indicators for their office electronic medical record. Some practices implemented no changes but suggested they are being discussed (6%). One had no changes implemented (6%). All changes were believed to benefit the overall coordination of care.
Other quality enhancement initiatives postsurvey included 3 regional continuing medical education programs solely dedicated to breast cancer screening, prevention, treatment, and high-risk patient populations. FCCC experts lectured on current treatment trends and offered tailored education to the needs identified from the NCCN guideline audit.
Future Directions, Discussion, and Conclusions medical oncologists strive for continuous quality improvement in their practices. The FCCCP program has developed a collaborative model of quality improvement to support medical oncology and rigorously define metrics that can be realistically implemented and monitored. The authors' most recent experience in stage II/III breast cancer suggests that although overall compliance is high, areas for education can be identified and improvements implemented to enhance patient care. More importantly, these metrics have been implemented and validated to be of proven benefit to practicing oncologists and the patients they serve.
